Explore in vivo CAR-T, nonviral editing delivery, cell targeting, and relevant measurement methods.
Delivery, expression, editing, and efficacy are different endpoints. Clearly distinguish cellular, animal, and human evidence.
Sources, selection, and corrections →67 public entity records, including 53 disclosed in vivo CAR-T developers or acquired platforms, plus 4 enabling partners, 5 adjacent platforms, 1 historical platform, and 4 other editing companies.
Entity counts are not independent program counts or a claim of 53 independently operating biotechs. Shared lineages and partnerships, including GRIT/Vivacta and Orna/Simnova, are identified. ReNAgade and Myeloid are not counted again.
Broad English and Chinese discovery searches followed by company pipelines, company-issued announcements, regulatory filings, and original research/meeting abstracts. Company claims are attributed; no inference of efficacy from registration, IND clearance, orphan status, or ex vivo programs. Publicly disclosed companies only; not a guarantee of exhaustive worldwide coverage.
Juventas / 合源生物 · Secondary landscape mentions in vivo assets; current primary pipeline could not be retrieved. Do not infer in vivo stage from CNCT19.
Vector BioPharma · Historical landscape listing; the former domain currently redirects to a domain-sale page. Current program status is unresolved.
Abintus Bio · Historical CAR-X disclosures found; current ownership and operating status require primary confirmation. Not presented as an independently active developer.
CARUS Bio / MDimune · Primary development page emphasizes macrophage CAR-M despite a CAR-T heading. T-cell-specific program not established.
Ingenium Therapeutics · Yale collaboration describes in vivo CAR-NK, not CAR-T.
Thunder Biotech · Discovered materials describe macrophage CAR-M; current primary CAR-T evidence not established.
Unicar-Therapy / 优卡迪 · Current primary in vivo program not verified. Conventional ssCART19/U01 clinical work must not be relabeled in vivo.
Vittoria; Cimeio; Entos; Strm.bio; ImmunoBio · No sufficiently specific current primary CAR-T program verified in this search. Generic delivery or ex vivo activity is insufficient.
Carisma Therapeutics · CAR-macrophage activity is not CAR-T; not added as a CAR-T developer.
Cytiva / Danaher; Nitto Denko · Enabling technology/manufacturing organizations, not additional independent biotech drug developers. Nitto partnership is documented under Hemogenyx.
ReNAgade; Myeloid; Ixaka · Former names or acquired asset lineages are not counted again as independent current companies. Orna and CREATE aliases retained; Ixaka current asset provenance not independently confirmed.
The first six companies in this field’s editorial order, not a separate selection or capability ranking. The full directory uses the same data and order.
Manage field companies & order →
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
AAVivo lists CD19 AVO-100, BCMA AVO-101, and dual BCMA/CD19 AVO-102 using T-cell-targeted AAV. The disclosed activities include vector production and construct optimization, not verified clinical dosing. AVO-103 is a TCR program and is kept separate from CAR-T.
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
Alaya is a preclinical in vivo CAR-T developer. Its disclosed polymeric nanoparticle platform encapsulates lentiviral CAR vectors for targeted T-cell transduction; this is a hybrid polymer/viral approach, not simply a nonviral polymer delivery system.
AllerGene proposes in vivo-delivered mRNA CAR-T to target mast cells in allergic disease. Its website establishes research intent, but does not establish a named clinical candidate, patient dosing, or validated allergy outcomes. It is distinct from Allogene Therapeutics.
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
Original online dates are retained. Guides use accessible articles or abstracts and do not replace reading the paper.
The authors report a polymer–lipid carrier that combines mRNA delivery with T-cell activation without an antibody targeting ligand. The study links the carrier to metabolic signaling and evaluates CAR expression and activity in preclinical cancer and fibrosis models. These findings do not establish safety or benefit in patients.
Qiannan Cao; Yingli Yao; Wenming Zheng; Hongqian Liu; Mingxia Jiang; Dayang Xie; Siting Zhang; Pijun Su; Huilin Yuan; Xiaoyuan Chen; Huapan Fang; Huayu Tian
DOI: 10.1038/s41563-026-02675-7
Manually selected historical and recent original announcements, not presented as today’s news. Source dates, including historical dates, are retained.
AbbVie announced completion of its Capstan acquisition on August 19, 2025, adding a targeted LNP platform for RNA delivery and in vivo cell engineering. This historical ownership event explains the company relationship. Candidate-stage descriptions in that release should be read at their original date, not as a current trial update.
Original announcement ↗